经浙江花园生物医药股份有限公司（以下简称"公司"）第七届董事会第八次会议 及第七届监事会第五次会议审议通过，决定于2025年4月15日（星期二）召开公司2024 年年度股东会。现将会议相关事项通知如下： | 证券代码：300401 | 证券简称：花园生物 公告编号：2025-010 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于召开 2024 年年度股东会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 （2）网络投票时间：2025年4月15日；其中，通过深圳证券交易所交易系统进行网 络投票的时间为：2025年4月15日9:15-9:25、9:30-11:30，下午13:00-15:00；通过深 圳证券交易所互联网投票系统进行投票的具体时间为：2025年4月15日9:15-15:00的任 意时间。 5、会议召开的方式：采取现场投票和网络投票相结合的方式 本次会议采取现场投票与网络投票相结合的方式，股东会股权登记日在册的公司股 东有权选择现场投票、网络投票中的一种方式行使表决权，如果同一 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2025-012 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 第七届监事会会第五次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、会议召开情况 浙江花园生物医药股份有限公司（以下简称"公司"）第七届监事会第五次会议于 2025 年 3 月 21 日在公司会议室以现场方式召开。会议通知于 2025 年 3 月 12 日以微信 及电子邮件等方式送达给全体监事。应出席监事 3 人，实际出席监事 3 人，会议的召集 和召开符合《公司法》《公司章程》的有关规定。会议经审议形成如下决议： 二、监事会会议审议情况 会议以记名投票的方式进行表决，经与会监事认真审议，形成如下决议： (一) 审议通过了《关于 2024 年度监事会工作报告的议案》。 具体内容详见刊登在巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。 表决情况：3 票同意，0 票反对，0 票弃权。 本议案尚需提交公司 2024 年年度股东会审议。 (二 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2025-011 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 第七届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏 一、会议召开情况 浙江花园生物医药股份有限公司（以下简称"公司"）第七届董事会第八次会议于 2025年3月21日在公司会议室以现场方式召开，会议通知于2025年3月12日以微信、电子 邮件等方式送达全体董事。会议应到董事9人，实到董事9人。本次会议由董事长邵徐君 先生主持，公司监事、高级管理人员列席了会议。会议的召集和召开符合《公司法》《公 司章程》的有关规定。 二、会议审议情况 会议以记名投票的方式进行表决，经与会董事认真审议，形成如下决议： (一) 审议通过了《关于2024年度董事会工作报告的议案》 公司董事会已就2024年度工作进行了分析总结。公司在任独立董事严建苗、厉国威、 杨启炜向董事会递交了《2024年度独立董事述职报告》，并将在公司2024年年度股东会 上述职。 公司董事会对 ...

浙江花园生物医药股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏 一、 审议程序 浙江花园生物医药股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日召开 第七届董事会独立董事专门会议、第七届董事会第八次会议、第七届监事会第五次会 议，审议通过了《关于 2024 年度利润分配方案的议案》。 1、独立董事专门会议审议情况 | 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-004 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 第七届董事会独立董事专门会议审议了该议案，独立董事认为：2024 年度公司 利润分配方案符合法律、法规及《公司章程》等相关规定，符合公司整体发展战略， 有利于公司的持续稳定健康发展，不存在损害公司及全体股东尤其中小股东的利益的 情形。独立董事同意将此议案提交公司董事会审议。 2、董事会审议情况 2025 年 3 月 21 日，公司召开的第七届董事会第八次会议，审议通过了《关于 2024 年度利润分配方案 ...

花园生物:2024年报净利润3.09亿 同比增长60.94% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.5700 | 0.3500 | 62.86 | 0.7000 | | 每股净资产（元） | 0 | 4.77 | -100 | 4.67 | | 每股公积金(元) | -0.1 | -0.01 | -900 | -0.07 | | 每股未分配利润(元) | 4.15 | 3.65 | 13.7 | 3.48 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 12.43 | 10.95 | 13.52 | 14.18 | | 净利润(亿元) | 3.09 | 1.92 | 60.94 | 3.84 | | 净资产收益率(%) | 10.17 | 7.30 | 39.32 | 15.89 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有 ...

Financial Performance - The company's revenue for 2024 reached ¥1,243,283,228.76, representing a 13.58% increase compared to ¥1,094,651,559.54 in 2023 [22]. - Net profit attributable to shareholders increased by 60.76% to ¥309,212,798.15 from ¥192,348,873.69 in the previous year [22]. - The net profit after deducting non-recurring gains and losses rose by 74.02% to ¥256,888,423.11, up from ¥147,616,823.26 in 2023 [22]. - The net cash flow from operating activities surged by 191.53% to ¥466,406,332.89, compared to ¥159,984,577.98 in the previous year [22]. - Basic earnings per share increased by 62.86% to ¥0.57 from ¥0.35 in 2023 [22]. - Total assets at the end of 2024 amounted to ¥5,612,645,527.96, a 6.69% increase from ¥5,260,592,068.07 in 2023 [22]. - Net assets attributable to shareholders grew by 11.24% to ¥3,218,400,077.44, compared to ¥2,893,130,267.00 at the end of 2023 [22]. - The weighted average return on equity for 2024 was 10.17%, up from 7.30% in the previous year [22]. Dividend Distribution - The company plans to distribute a cash dividend of 1.14 CNY per 10 shares to all shareholders, based on a total share capital of 543,467,249 shares [6]. - The company will not issue bonus shares or increase capital reserves in the current profit distribution plan [6]. - For the fiscal year 2024, the company will distribute a cash dividend of RMB 1.14 per 10 shares, amounting to RMB 61,955,266.39, with no stock bonus or capital increase [144]. - The company's net profit for 2024 is reported at RMB 309,212,798.15, with available distributable profits of RMB 1,753,020,180.53 [144]. Risk Management - The company emphasizes the importance of understanding risks related to industry cyclicality, drug price declines, and procurement failures in the vitamin sector [5]. - Future development plans and forward-looking statements do not constitute substantial commitments to investors, highlighting the need for cautious decision-making [5]. - The management discussion section outlines potential risks and challenges the company may face in its operations [5]. - The company recognizes risks related to vitamin price fluctuations, which significantly impact revenue due to the high proportion of vitamin product sales [104]. - The company faces project investment risks, as the construction of funded projects may encounter uncertainties in progress, implementation, and effectiveness [104]. - The company is exposed to risks from changes in medical reform policies that could alter market competition and business models [104]. - The company anticipates continued downward pressure on drug prices due to government policies aimed at reducing medical costs, which may negatively affect profitability [104]. Research and Development - The company plans to continue expanding its product lines and enhance R&D efforts in innovative drugs and technologies [22]. - The company emphasizes R&D investment and has a sustainable product development pipeline for new product research and technology innovation [50]. - The company has three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials [51]. - The company is currently conducting multiple R&D projects aimed at enriching its product line and enhancing market competitiveness [77]. - The company has ongoing projects in various stages, with several products awaiting approval for market launch [77]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies and potential mergers and acquisitions to strengthen its market position [22]. - The company has established a comprehensive vitamin D3 industrial chain, becoming the only global producer with this capability [53]. - The company has outlined a strategy to enhance its product offerings and market expansion efforts in the future [166]. Environmental and Social Responsibility - The report will cover significant environmental and social responsibility issues faced by the company [10]. - The company has established a standardized hazardous waste storage facility and strictly follows electronic tracking for hazardous waste disposal [153]. - The company adheres to various environmental standards for air and water pollutants, ensuring compliance with industry regulations [153]. - The company achieved an A-level performance rating in environmental management from Zhejiang Province in 2024 [158]. - The company emphasizes a green development philosophy, focusing on source reduction, process control, and end treatment of waste [155]. Corporate Governance - The company maintains a complete and independent business system, ensuring no interference from controlling shareholders [121]. - The company has a robust organizational structure with independent operation of its internal governance bodies [121]. - The management team includes experienced professionals, with the current general manager, Ma Huanzheng, having been with the company since 2000 [123]. - The company has a structured decision-making process for determining the remuneration of its board members and executives [128]. - The board of directors held a total of 8 meetings during the reporting period, with all members actively participating [131]. Financial Management - The company has maintained effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report [151]. - The internal control audit report received a standard unqualified opinion, confirming alignment with the self-evaluation report [151]. - The company has implemented a continuous optimization of its internal control management system to enhance risk prevention capabilities [150]. - The company has established measures to ensure compliance with public commitments made by its controlling shareholders and management personnel [166]. Employee Management - The company is committed to improving employee salary levels and welfare, contributing to rural revitalization and common prosperity [161]. - The total number of employees at the end of the reporting period is 1,021, with 211 in the parent company and 810 in major subsidiaries [138]. - The professional composition includes 567 production personnel, 51 sales personnel, 229 technical personnel, 60 financial personnel, and 114 administrative personnel [138]. - The company has established a comprehensive training system to enhance employee skills and align with strategic goals [140]. Subsidiaries and Investments - The company established Zhejiang Garden Biomedicine Engineering Co., Ltd. with a registered capital of RMB 200 million, holding a 90% stake [176]. - The company has not sold any major assets during the reporting period [101]. - The actual amount of related party transactions during the reporting period was CNY 114.82 million, while the approved transaction amount for 2024 is expected to be CNY 160 million [183].

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-003 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于可转换公司债券 2025 年付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2、债权登记日：2025年3月5日（星期三） 3、付息日：2025年3月6日（星期四） 4、除息日：2025年3月6日（星期四） 5、本次付息期间及票面利率：计息期间为2024年3月6日至2025年3月5日，票面利 率为0.50%。 6、本次付息的债权登记日为2025年3月5日。凡在2025年3月5日（含）前买入并持 有本期债券的投资者享有本次派发的利息，2025年3月5日（含）前卖出本期债券的投资 者不享有本次派发的利息。在付息债权登记日前（包括付息债权登记日）申请转换成公 司股票的可转换公司债券，公司不再向其持有人支付本计息年度及以后计息年度的利 息。 7、下一付息期起息日：2025年3月6日 8、下一年度票面利率：1.0% 浙江花园生物医药股份有限公 ...

Financial Performance - The net profit attributable to shareholders is expected to be between 300 million and 350 million yuan, representing a year-on-year growth of 55.97% to 81.96%[3] - The net profit after deducting non-recurring gains and losses is projected to be between 250 million and 290 million yuan, indicating a year-on-year increase of 69.36% to 96.45%[3] - The overall operating revenue is expected to rise by around 13%, with total gross profit increasing by approximately 10%[5] Segment Performance - Revenue from the vitamin segment increased by approximately 55%, with gross profit rising by about 77%[5] Expenses and Gains - Marketing expenses for pharmaceutical products decreased by about 24% compared to the previous year[5] - The company recognized asset disposal gains of approximately 31 million yuan from the relocation of its Hangzhou subsidiary[5] - Non-recurring gains and losses are estimated to impact net profit by 50 million to 60 million yuan, mainly from subsidiary relocation asset disposal gains and government subsidies[6] Financial Reporting - The company has communicated with the accounting firm regarding the preliminary financial data, with no significant discrepancies reported[4] - The financial data provided is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[7] - The performance forecast period is from January 1, 2024, to December 31, 2024[3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 证券代码：300401 | 证券简称：花园生物 公告编号：2025-001 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于 2024 年第四季度可转换公司债券转股情况公告 （三）可转换公司债券转股期限 重要内容提示： 1、"花园转债"（债券代码：123178）转股期限为2023年9月11日至2029年3月5日； 最新的转股价格为人民币13.56元/股。 2、2024年第四季度，共有404张"花园转债"完成转股（票面金额共计人民币 40,400.00元），合计转成2,973股"花园生物"股票（证券代码：300401）。 3、截至2024年第四季度末，"花园转债"剩余债券张数为11,760,281张，剩余票面 总额为人民币1,176,028,100.00元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，浙江花园生物医药股份有限公司（以 下简称"公司"）现将2024 ...

财联社12月31日电，花园生物公告称，公司拟在澳门设立子公司，主要从事大健康的研发、生产和销 售。 公司名称暂定为花园力维(澳门)生物科技有限公司，注册资本为1,000万澳门元。 经营范围包括化学药、生物制品、中药、保健品、保健食品、化妆品、医疗器械的研发、生产及销售 等。 公司将持股80%，全资子公司浙江花园营养科技有限公司持股20%。 ...